Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability': https://t.co/TaMTzZIz3W

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report.

$ATRA #MS #biotech #healthcare #stocks @Atarabio https://t.co/MVhK5kJLYp